ZA94248B - Potentiation of temozolomide in human tumour cells - Google Patents

Potentiation of temozolomide in human tumour cells

Info

Publication number
ZA94248B
ZA94248B ZA94248A ZA94248A ZA94248B ZA 94248 B ZA94248 B ZA 94248B ZA 94248 A ZA94248 A ZA 94248A ZA 94248 A ZA94248 A ZA 94248A ZA 94248 B ZA94248 B ZA 94248B
Authority
ZA
South Africa
Prior art keywords
potentiation
temozolomide
tumour cells
human tumour
human
Prior art date
Application number
ZA94248A
Other languages
English (en)
Inventor
John Colin Baer
Edward Stuart Newlands
Joseph Anthony Rafferty
Azadeh Alison Freeman
Amanda Jean Watson
Geoffrey Paul Margison
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Publication of ZA94248B publication Critical patent/ZA94248B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA94248A 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells ZA94248B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US475493A 1993-01-14 1993-01-14

Publications (1)

Publication Number Publication Date
ZA94248B true ZA94248B (en) 1994-07-13

Family

ID=21712364

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94248A ZA94248B (en) 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells

Country Status (20)

Country Link
EP (2) EP0922458A1 (sk)
JP (1) JPH08505615A (sk)
KR (1) KR100352046B1 (sk)
CN (1) CN1277541C (sk)
AU (1) AU5838494A (sk)
CA (1) CA2153775C (sk)
CZ (1) CZ286550B6 (sk)
FI (1) FI953423A (sk)
HU (1) HUT72665A (sk)
IL (1) IL108328A (sk)
MX (1) MX9400434A (sk)
MY (1) MY116474A (sk)
NO (1) NO952781L (sk)
PL (1) PL175842B1 (sk)
RU (1) RU2148401C1 (sk)
SK (1) SK282452B6 (sk)
TW (1) TW414710B (sk)
UA (1) UA29466C2 (sk)
WO (1) WO1994015615A1 (sk)
ZA (1) ZA94248B (sk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
WO2000033823A2 (en) * 1998-12-07 2000-06-15 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
SG161101A1 (en) * 2002-02-22 2010-05-27 Schering Corp Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same
WO2003101474A1 (en) * 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
CN100350974C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100431605C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100402091C (zh) * 2005-02-03 2008-07-16 山东蓝金生物工程有限公司 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
DK2531206T3 (en) 2010-02-04 2017-09-11 Morphotek Inc CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USE THEREOF
KR101972173B1 (ko) 2010-05-11 2019-04-24 프레드 헛친슨 켄서 리서치 센터 클로로톡신 변이체, 접합체, 및 이의 사용 방법
CN103169664B (zh) * 2011-12-25 2015-04-22 复旦大学 一种rgd肽修饰的双层载药纳米粒及其制备方法
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer

Also Published As

Publication number Publication date
TW414710B (en) 2000-12-11
JPH08505615A (ja) 1996-06-18
CA2153775C (en) 2000-11-14
CZ286550B6 (cs) 2000-05-17
RU2148401C1 (ru) 2000-05-10
WO1994015615A1 (en) 1994-07-21
IL108328A0 (en) 1994-04-12
CN1117711A (zh) 1996-02-28
PL309915A1 (en) 1995-11-13
KR100352046B1 (ko) 2003-09-03
NO952781L (no) 1995-09-13
FI953423A0 (fi) 1995-07-13
HU9502117D0 (en) 1995-09-28
CA2153775A1 (en) 1994-07-21
AU5838494A (en) 1994-08-15
HUT72665A (en) 1996-05-28
EP0679086A1 (en) 1995-11-02
UA29466C2 (uk) 2000-11-15
CZ179795A3 (en) 1996-04-17
FI953423A (fi) 1995-08-23
PL175842B1 (pl) 1999-02-26
EP0922458A1 (en) 1999-06-16
SK89295A3 (en) 1996-06-05
KR960700063A (ko) 1996-01-19
IL108328A (en) 2010-05-31
MX9400434A (es) 1994-07-29
NO952781D0 (no) 1995-07-13
MY116474A (en) 2004-02-28
SK282452B6 (sk) 2002-02-05
CN1277541C (zh) 2006-10-04

Similar Documents

Publication Publication Date Title
IL108328A0 (en) Potentiation of temozolomide in human tumour cells
HK1015280A1 (en) Use of epinastine in the treatment of pain
EP0623020A4 (en) PYROPHEOPHORBIDES AND THEIR USE IN PHOTODYNAMIC THERAPY.
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
HUP9801634A3 (en) Genetically modified cells and their use in prevention or therapy of disease
AU4786093A (en) Non-peptidic surrogates of the ldv sequence and their use in the treatment of inflammation, autoimmune diseases and tumour progression
GR3033135T3 (en) Bicyclic isothiourea derivatives useful in therapy
GB2281863B (en) Improvements in relation to medical diathermy
ZA943549B (en) Cell surface protein expressed on human cortical thymocyte and their use
AU9071291A (en) Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy
ZA983740B (en) Novel amidine derivatives and their use in therapy
AU6371198A (en) Potentiation of temozolomide in human tumour cells
AU4980693A (en) Improvements in skin plasters
ZA95508B (en) Use of flavolignans as adjuvants in tumour therapy
GB9721075D0 (en) Materials and methods relating to the stimulation of cells
AU8727498A (en) Substituted triazine compounds and their use in medicine
ZA941939B (en) Therapeutic triazine compounds and use
GB2292219B (en) Polymorphisms in human phosphoglucomutase-1
GB9523066D0 (en) Compounds and their therapeutic use
AP9400627A0 (en) Therapeutic triazine compounds and use
GB9312780D0 (en) Therapeutic and cosmetic treatment
SI1011649T1 (en) Use of endipalene in the treatment of psoriasis
GB9316836D0 (en) Human cell lines
ZA96972B (en) Bicyclic isothiourea derivatives useful in therapy
IL105012A0 (en) Skin treatment gel